JP2018506555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506555A5 JP2018506555A5 JP2017544887A JP2017544887A JP2018506555A5 JP 2018506555 A5 JP2018506555 A5 JP 2018506555A5 JP 2017544887 A JP2017544887 A JP 2017544887A JP 2017544887 A JP2017544887 A JP 2017544887A JP 2018506555 A5 JP2018506555 A5 JP 2018506555A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- receptor
- receptor agonist
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120726P | 2015-02-25 | 2015-02-25 | |
| US62/120,726 | 2015-02-25 | ||
| PCT/US2016/019368 WO2016138138A1 (en) | 2015-02-25 | 2016-02-24 | 5ht agonists for treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081127A Division JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506555A JP2018506555A (ja) | 2018-03-08 |
| JP2018506555A5 true JP2018506555A5 (https=) | 2018-04-19 |
| JP6884703B2 JP6884703B2 (ja) | 2021-06-09 |
Family
ID=56789223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544887A Active JP6884703B2 (ja) | 2015-02-25 | 2016-02-24 | 障害を治療するための５ｈｔ作動薬 |
| JP2020081127A Pending JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
| JP2021128790A Active JP7846506B2 (ja) | 2015-02-25 | 2021-08-05 | 障害を治療するための５ｈｔ作動薬 |
| JP2022091363A Pending JP2022116307A (ja) | 2015-02-25 | 2022-06-06 | 障害を治療するための５ｈｔ作動薬 |
| JP2023169390A Pending JP2024009839A (ja) | 2015-02-25 | 2023-09-29 | 障害を治療するための５ｈｔ作動薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081127A Pending JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
| JP2021128790A Active JP7846506B2 (ja) | 2015-02-25 | 2021-08-05 | 障害を治療するための５ｈｔ作動薬 |
| JP2022091363A Pending JP2022116307A (ja) | 2015-02-25 | 2022-06-06 | 障害を治療するための５ｈｔ作動薬 |
| JP2023169390A Pending JP2024009839A (ja) | 2015-02-25 | 2023-09-29 | 障害を治療するための５ｈｔ作動薬 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10874643B2 (https=) |
| EP (4) | EP4696377A3 (https=) |
| JP (5) | JP6884703B2 (https=) |
| KR (3) | KR102385665B1 (https=) |
| CN (2) | CN113546174A (https=) |
| AU (3) | AU2016222804C1 (https=) |
| BR (1) | BR112017018297B1 (https=) |
| CA (2) | CA3204599A1 (https=) |
| CY (1) | CY1125360T1 (https=) |
| DK (1) | DK3261640T3 (https=) |
| EA (2) | EA201992474A3 (https=) |
| ES (2) | ES3060954T3 (https=) |
| HR (1) | HRP20220822T1 (https=) |
| HU (1) | HUE059559T2 (https=) |
| LT (1) | LT3261640T (https=) |
| PL (1) | PL3261640T3 (https=) |
| PT (1) | PT3261640T (https=) |
| RS (1) | RS63426B1 (https=) |
| SI (1) | SI3261640T1 (https=) |
| SM (1) | SMT202200276T1 (https=) |
| WO (1) | WO2016138138A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| HUE059559T2 (hu) | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| GB201620095D0 (en) * | 2016-11-28 | 2017-01-11 | Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And | Novel use |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| ES3024232T3 (en) | 2015-12-22 | 2025-06-04 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| SG11201900975XA (en) | 2016-08-24 | 2019-03-28 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12268683B2 (en) | 2018-07-18 | 2025-04-08 | The Regents Of The University Of California | Compounds and methods for synergistic activation of M channels |
| JP2021530541A (ja) * | 2018-07-27 | 2021-11-11 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | てんかんの治療方法 |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| WO2020243349A1 (en) * | 2019-05-29 | 2020-12-03 | The Regents Of The University Of California | Methods and compositions for treating epilepsy |
| EP3791873A1 (en) | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies |
| CN120267677A (zh) * | 2019-10-23 | 2025-07-08 | 纽罗塞克医疗公司 | 用gabaa受体调节剂的癫痫状况的治疗 |
| ES3056138T3 (en) * | 2019-10-23 | 2026-02-18 | Maplight Therapeutics Inc | Methods of treating the symptoms of autism spectrum disorder |
| KR20210054684A (ko) | 2019-11-06 | 2021-05-14 | 동국대학교 경주캠퍼스 산학협력단 | 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| WO2021113834A1 (en) * | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| KR102476771B1 (ko) * | 2020-05-08 | 2022-12-13 | 광운대학교 산학협력단 | 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20240189240A1 (en) * | 2021-03-25 | 2024-06-13 | Maplight Therapeutics, Inc. | Pharmaceutical compositions comprising zolmitriptan |
| EP4346804A4 (en) * | 2021-06-01 | 2025-05-07 | Arena Pharmaceuticals, Inc. | TREATMENT PROCEDURES |
| JP2024521399A (ja) * | 2021-06-10 | 2024-05-31 | ニューレリス、インク． | 小児患者における発作性障害を治療するための組成物および方法 |
| JP2024529509A (ja) * | 2021-07-30 | 2024-08-06 | エピジェニクス セラピューティクス インコーポレーテッド | クレミゾール製剤 |
| WO2023107965A1 (en) * | 2021-12-06 | 2023-06-15 | Terran Biosciences, Inc. | Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc) |
| WO2023144166A1 (en) | 2022-01-26 | 2023-08-03 | Neurolixis | Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| US11974992B2 (en) | 2022-01-26 | 2024-05-07 | Neurolixis | Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| US20250295611A1 (en) * | 2022-04-27 | 2025-09-25 | Tessellate Therapeutics Inc. | Methods of treating 5ht2a receptor-mediated conditions |
| IL315086A (en) | 2022-06-09 | 2024-10-01 | Diamond Therapeutics Inc | Amorphous (A-polymorphic) psilocybin |
| WO2024118280A1 (en) * | 2022-11-30 | 2024-06-06 | Mind Medicine, Inc. | 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action |
| CN119564685B (zh) * | 2024-12-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| US7326536B2 (en) | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| WO2005032329A2 (en) | 2003-08-22 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-hcv agents |
| US20050215589A1 (en) * | 2003-09-03 | 2005-09-29 | Roger Crossley | Inhibitors of 5-HT2A receptor |
| EP1787679A1 (en) | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| US7635710B2 (en) * | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| WO2008036586A2 (en) | 2006-09-20 | 2008-03-27 | Waters Investments Limited | Apparatus and methods of fluid chromatography |
| KR101475248B1 (ko) | 2007-04-06 | 2014-12-22 | 코닌클리케 필립스 엔.브이. | 공기 오염 센서 시스템 |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| EP2152276A4 (en) | 2007-05-09 | 2011-09-14 | Traffick Therapeutics Inc | SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING |
| JP5715820B2 (ja) | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
| KR100925176B1 (ko) | 2007-09-21 | 2009-11-05 | 한국전자통신연구원 | 지리 정보를 이용한 네트워크 상태 표시장치 및 방법 |
| KR20100137473A (ko) * | 2008-02-19 | 2010-12-30 | 아돌로 코포레이션 | 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체 |
| JP2011518154A (ja) | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−１−｛２−［４’−（３−メトキシプロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの合成に有用なプロセス |
| CN102088990A (zh) | 2008-05-16 | 2011-06-08 | 阿尔伯维塔公司 | 癫痫的治疗 |
| US20110217265A1 (en) | 2008-09-23 | 2011-09-08 | Glenn Jeffrey S | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function |
| EP2408448A4 (en) | 2009-03-18 | 2012-09-19 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| JP5656980B2 (ja) | 2009-05-13 | 2015-01-21 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー含有の置換芳香族トリアジン化合物 |
| CN102666537A (zh) | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| WO2014123909A1 (en) | 2013-02-05 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2015096119A1 (zh) | 2013-12-27 | 2015-07-02 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| HUE059559T2 (hu) | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2016
- 2016-02-24 HU HUE16756282A patent/HUE059559T2/hu unknown
- 2016-02-24 EP EP25211402.0A patent/EP4696377A3/en active Pending
- 2016-02-24 AU AU2016222804A patent/AU2016222804C1/en active Active
- 2016-02-24 LT LTEPPCT/US2016/019368T patent/LT3261640T/lt unknown
- 2016-02-24 CA CA3204599A patent/CA3204599A1/en active Pending
- 2016-02-24 DK DK16756282.6T patent/DK3261640T3/da active
- 2016-02-24 ES ES22157142T patent/ES3060954T3/es active Active
- 2016-02-24 KR KR1020177026528A patent/KR102385665B1/ko active Active
- 2016-02-24 ES ES16756282T patent/ES2920886T3/es active Active
- 2016-02-24 SI SI201631545T patent/SI3261640T1/sl unknown
- 2016-02-24 KR KR1020227011498A patent/KR20220048045A/ko not_active Ceased
- 2016-02-24 RS RS20220598A patent/RS63426B1/sr unknown
- 2016-02-24 EP EP22157142.5A patent/EP4043016B1/en active Active
- 2016-02-24 PT PT167562826T patent/PT3261640T/pt unknown
- 2016-02-24 EA EA201992474A patent/EA201992474A3/ru unknown
- 2016-02-24 BR BR112017018297-1A patent/BR112017018297B1/pt active IP Right Grant
- 2016-02-24 CN CN202111041649.4A patent/CN113546174A/zh active Pending
- 2016-02-24 US US15/552,784 patent/US10874643B2/en active Active
- 2016-02-24 SM SM20220276T patent/SMT202200276T1/it unknown
- 2016-02-24 EA EA201791882A patent/EA201791882A1/ru unknown
- 2016-02-24 KR KR1020237037303A patent/KR20230152844A/ko active Pending
- 2016-02-24 HR HRP20220822TT patent/HRP20220822T1/hr unknown
- 2016-02-24 EP EP19211183.9A patent/EP3632434A1/en not_active Withdrawn
- 2016-02-24 WO PCT/US2016/019368 patent/WO2016138138A1/en not_active Ceased
- 2016-02-24 CA CA2977135A patent/CA2977135C/en active Active
- 2016-02-24 JP JP2017544887A patent/JP6884703B2/ja active Active
- 2016-02-24 PL PL16756282.6T patent/PL3261640T3/pl unknown
- 2016-02-24 CN CN201680023991.2A patent/CN107530326B/zh active Active
- 2016-02-24 EP EP16756282.6A patent/EP3261640B1/en active Active
-
2019
- 2019-11-08 US US16/679,112 patent/US11648237B2/en active Active
-
2020
- 2020-05-01 JP JP2020081127A patent/JP2020143087A/ja active Pending
- 2020-10-28 US US17/082,929 patent/US20210154171A1/en active Pending
-
2021
- 2021-06-23 AU AU2021204261A patent/AU2021204261B2/en active Active
- 2021-08-05 JP JP2021128790A patent/JP7846506B2/ja active Active
-
2022
- 2022-05-16 AU AU2022203274A patent/AU2022203274B2/en active Active
- 2022-06-06 JP JP2022091363A patent/JP2022116307A/ja active Pending
- 2022-06-22 CY CY20221100428T patent/CY1125360T1/el unknown
-
2023
- 2023-03-30 US US18/192,955 patent/US12447144B2/en active Active
- 2023-09-29 JP JP2023169390A patent/JP2024009839A/ja active Pending
-
2025
- 2025-05-29 US US19/222,750 patent/US20260083706A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506555A5 (https=) | ||
| US20240041848A1 (en) | Methods and compositions for treating herpesvirus induced conditions | |
| US11072648B2 (en) | Mast cell stabilizers for treatment of fever | |
| JP2018521042A5 (https=) | ||
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| JP2024507810A5 (https=) | ||
| CN103764133A (zh) | 克仑特罗在治疗自闭症上的用途 | |
| WO2012056246A1 (en) | Combination treatment of major depressive disorder | |
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан | |
| Bang et al. | Paroxetine controlled release | |
| US20110039926A1 (en) | Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients | |
| JP2011157395A5 (https=) | ||
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Suvar | Antidepressants | |
| TW200940049A (en) | Associations for obtaining medicaments for the treatment of bipolar disorders | |
| JP2007513095A5 (https=) | ||
| Bhagat et al. | Nabilone: A Synthetic Cannabinoid in Postoperative Nausea and Vomiting | |
| Nedić et al. | Rapidity in reducing depressive symptomatology: Moclobemide vs amitriptyline | |
| HK1254168B (en) | Combinations of a nucleoside analog and an inducing agent for use in treating herpesvirus-induced conditions | |
| JP2007508242A (ja) | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 |